Ricerca adds to DMPK team

William DeMaio joins from Wyeth Research

Ricerca, a US-based preclinical contract research organisation (CRO) providing services to the biopharmaceutical industry, has added William DeMaio, as senior director of its drug metabolism and pharmacokinetics (DMPK) department.

DeMaio joins a team of bioanalytical and drug metabolism scientists that provides integrated pharmaceutical development services and analytical problem solving capabilities, offering support for Ricerca’s discovery and preclinical development programmes.

Prior to joining Ricerca, DeMaio was associate director of biotransformation at Wyeth Research (now Pfizer) in Collegeville, Pennsylvania, where he was responsible for drug metabolite identification and metabolism characterisation by mass spectrometry. He has expertise in chromatography, mass spectrometry, structural elucidation and drug development, as well as operating GLP-compliant bioanalytical and metabolism operations and training analysts in use of LC/MS equipment and data analysis.

You may also like

Research & Development

Celerion and Ricerca Biosciences to provide integrated service for biosimilars

Will test viability of a potential biosimilar early in the process
Research & Development

Ricerca announces similarity analysis service

Foresight allows compound assay results to be compared against pharmacologically active compounds
Research & Development

Ricerca and LSP agree business development collaboration

Ricerca will expand its presence in Japan, Korea and overall Asian market
Regulatory

Ricerca completes purchase of MDS Pharma businesses

The acquisition gives Ohio-based Ricerca more capacity and capabilities.
Research & Development

MDS to sell early stage business to Ricerca

MDS Pharma Services is to sell its remaining discovery and pre-clinical operations to Ohio-based Ricerca Biosciences for US$45m.
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Subscribe now